Rigel Pharmaceuticals (RIGL) EBT (2010 - 2026)

Rigel Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• On a quarterly basis, EBT rose 1.27% year-over-year to $11.7 million in Q1 2026; TTM through Mar 2026 was $122.0 million, a 219.94% increase from a year earlier, with the FY2025 full-year figure at $121.8 million, up 563.33% from the prior year.
• EBT eased to $11.7 million in Q1 2026 per RIGL's latest filing, from $22.7 million in the prior quarter.
• Across five years, EBT topped out at $60.0 million in Q2 2025 and bottomed at -$27.4 million in Q1 2022.
• The 5-year median for EBT is $11000.0 (2023), against an average of $3.9 million.
• Across the five-year window, EBT plunged 166.5% in 2022 and soared 138281.82% in 2024, its largest moves.
• Year by year, EBT stood at $1.4 million in 2022, then plunged by 99.21% to $11000.0 in 2023, then surged by 138281.82% to $15.2 million in 2024, then soared by 49.22% to $22.7 million in 2025, then tumbled by 48.68% to $11.7 million in 2026.
• Per Business Quant, the three latest RIGL EBT figures stand at $11.7 million (Q1 2026), $22.7 million (Q4 2025), and $27.6 million (Q3 2025).